WELIREG Plus LENVIMA Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously ...
Researchers examined whether CDK4/6 inhibitors lead to better overall survival when used as first- or second-line treatment.
The approval was based on a cohort of treatment-naïve patients in the Beamion LUNG-1 trial who had unresectable or metastatic, non-squamous NSCLC with HER2 tyrosine kinase domain mutations.
A recent review identifies interleukin-36 (IL-36) as a transformative driver of vascular inflammation, revealing that serum ...
In sum, the nonapeptide Oxytocin presents as a structurally well-defined peptide with a receptor system that is widely ...
The ATTC platform integrates monoclonal antibodies with small-molecule inhibitor payloads to provide dual mechanisms of ...
Less than a year after cutting roughly 30% of its employees, BioAtla is letting go of an even larger chunk of its workforce as it considers its future, which could include strategic partnerships and ...
Shifting the focus from organ to biomarker has unlocked new options for rare and advanced cancers. Uneven efficacy, diagnostic access, and regulation still slow clinical rollout.
Acquisition will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial assets and a robust ...
Pharmaceutical Technology on MSN
Kairos Pharma signs deal for Celyn Therapeutics’ CL-273
The acquisition aims to accelerate the development of targeted therapies for EGFR mutant NSCLC patients globally.
Experts agree that combination approaches, which may or may not include chemotherapy, will drive improved patient outcomes in ...
Pramorelin, also known in scientific literature as a synthetic ghrelin receptor agonist, has emerged as a notable peptide within the broader landscape of endocrine and metabolic research. Its primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results